ZBTB20 and gastric cancer: The results are shown in Table 6: The rs9288999 of ZBTB20 may reduce the risk of gastric cancer in the study population with BMI < 24 under the allele model (OR = 0.68, P=0.004), homozygous model (OR = 0.41, P=0.001), recessive model (OR = 0.46, P=0.002) and additive model (OR = 0.67, P=0.004); on the contrary, rs9841504 may increase the risk of gastric cancer in the study population with BMI> 24 under the homozygous model (OR = 11.9, P=0.028) and recessive model (OR = 12.29, P=0.026).